

**COMMERCE COMMITTEE TESTIMONY
FEBRUARY 27, 2014**

Cato T. Laurencin, M.D., Ph.D., University Professor

**Chief Executive Officer, Connecticut Institute
for Clinical and Translational Science,
Director, The Raymond and Beverly Sackler Center for
Biomedical, Biological, Physical and Engineering Sciences,
Director, The Institute for Regenerative Engineering,
The University of Connecticut**

H.B. No. 5042 AN ACT CONCERNING THE REGENERATIVE MEDICINE RESEARCH FUND.

It is a pleasure for me to provide my very strong support for H.B. No. 5042, an act which both extends the original stem cell act funding for two years, and seeks to broaden the scope of research to be supported. Since the original stem cell research support legislation was enacted, we at the Institute for Regenerative Engineering have worked in research aimed at creating living functional tissue for the purposes of regenerating, repairing or replacing tissue and organs lost due to damage, aging, disease, or congenital defect. This legislation is precisely focused on this goal, and I applaud the Governor and the legislature for their move in this direction.

More precisely, and probably a better term than Regenerative Medicine, we believe that a new field has emerged with this purpose, one that we are pioneering here in Connecticut. It is a field called Regenerative Engineering. Regenerative Engineering is defined as tissue engineering, combined with new advances in stem cell science, advanced materials science and developmental biology for the purposes of regeneration of complex tissues. The editors of Science Magazine recently asked us to discuss the future of stem cell, materials and associated research, and our article published in Science Translational Medicine (which we include here) describes what we see as the future of the field.

Already we have witnessed the powerful potential of Regenerative Engineering.

- 1) In the past 12 months over 5 MM in outside grant funding awards have been made to the Institute for Regenerative Engineering.
- 2) A new textbook describing the field has been published in the last 6 months.
- 3) A National Symposium on Regenerative Engineering has been planned for this April with scientists around the country to be in attendance.
- 4) Two new companies (Soft Tissue Regeneration, and Natural Polymer Devices) have emerged using principles of Regenerative Engineering. These companies are located in Connecticut.
- 5) Through the Raymond and Beverly Sackler Foundation, an endowment has been established at the University of Connecticut, creating a center dedicated to developing Regenerative Engineering, as it is a field that fosters the Convergence of Stem Cell Technology, Materials Technology and Tissue Engineering.

- 6) The Institute for Regenerative Engineering has just been named a Center for the Armed Forces Institute for Regenerative Medicine (AFIRM). Our winning this award was due to the rapid clinical translation potential of Regenerative Engineering in treating the warfighter.

We see this new field as not only creating phenomenal discoveries, but also leveraging outside funding from grants, philanthropy, and industrial investments. At the same time we believe Regenerative Engineering as a field has an advantage in growing jobs. Researchers involved at our Institute are already scientific founders of companies that utilize Regenerative Engineering principles. Properly nurtured, this field I believe will foster unprecedented treatment cures while providing financial growth in life science and allied industries.

While there are a number of Regenerative Medicine initiatives around the country, there is yet to be a state initiative dedicated to advancing Regenerative Engineering. I believe we in Connecticut have an incredible opportunity with this bill to take on a national leadership role in this new field. I urge passage of this bill.

Thank you for your kind attention, and all your support for Science in Connecticut.



Dr. Cato T. Laurencin is the Van Dusen Distinguished Professor of Orthopaedic Surgery and the Director of both the Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering Sciences, and the Institute for Regenerative Engineering at the University of Connecticut. E-mail: laurencin@uchc.edu



Dr. Yusuf Khan is a member of the Institute for Regenerative Engineering and an Assistant Professor in the Department of Orthopaedic Surgery at the University of Connecticut.

Citation:

C. T. Laurencin, Y. Khan, Regenerative engineering, *Sci. Transl. Med.* 4, 160ed9 (2012).

10.1126/scitranslmed.3004467

BIOMATERIALS INNOVATION

Regenerative Engineering

THIS YEAR MARKS THE 25TH ANNIVERSARY OF THE FIELD OF TISSUE ENGINEERING. The bioengineer Y. C. Fung first proposed the term at a 1987 meeting of the National Science Foundation's Director for Engineering, Bioengineering and Research to Aid the Handicapped Program. Great interest in the field heightened with the paper by Langer and Vacanti in *Science* (1), which described it as "an interdisciplinary field that applies the principles of engineering and life sciences toward the development of biological substitutes that restore, maintain, or improve tissue function or a whole organ." Laurencin further defined it as "the application of biological, chemical and engineering principals towards the repair, restoration, or regeneration of living tissue using biomaterials, cells, and factors alone or in combination" (2).

Over the past 25 years, advances have been made in biomaterials-based tissue engineering research to repair organ systems. In the past decade, three areas of technology have emerged and have added to the "toolbox" available to biomaterials scientists and engineers, presenting exciting possibilities to moving beyond maintaining or repairing tissue to regenerating them. First, our appreciation of phenomena taking place in the nano-regime gained appreciation in the late 1990s and ushered in nanotechnology as a tool for engineering tissues, and advances in materials science have allowed us to harness those tools. Second, stem cell science has matured to where the use of stem cells is an everyday tool. We now have a deeper understanding of both adult and embryonic stem cells, and have developed and characterized induced pluripotent stem cells. Third, we have gained a more sophisticated understanding of developmental biology mechanisms in the salamander and the newt, and the role of the blastema in regeneration which has furthered our efforts in wound repair and regeneration. Each of these scientific advances has matured to the extent that they are now regarded as tools rather than simply concepts and ideas. It is with this in mind that we believe the future of tissue engineering lies in what can be termed "regenerative engineering."

We define regenerative engineering as the integration of tissue engineering with advanced material science, stem cell science, and areas of developmental biology. Regenerative engineering will harness and expand these newly developed tools toward the regeneration of complex tissues (3). Whereas tissue engineering sought to encourage interdisciplinary teams from the fields of engineering, science, and medicine, we see regenerative engineering as an expansion of this approach—a "convergence" (4) of tissue engineering with the three distinct fields above, to move beyond interdisciplinary scientific teams with siloed expertise toward an era in which scientists, engineers, physicists, and clinicians will have integrated training that spans these disciplines.

ADVANCED BIOMATERIALS SCIENCE

Tissue engineering has largely focused on the restoration and repair of individual tissues and organs, but over the past 25 years, scientific, engineering, and medical advances have allowed us to start considering the regeneration of complex tissues and biological systems. For instance, the traditional tissue engineering approach has used biomaterials from a limited pool of biodegradable and nondegradable polymers and ceramics to form three-dimensional structures to facilitate repair. The choice of biomaterials, however, has increased over the past 25 years to include polymers that can be designed with a range of mechanical properties, degradation rates, and chemical functionality. The polyphosphazenes are one good example. These and other advanced materials support a greater diversity of applications because their chemical versatility allows the polymer to be designed for a specific tissue or application rather than relying on extant materials repurposed as biomaterials.

Nanoscale control over scaffold architecture has led to a greater understanding of cellular sensitivity to topography. These tools are now being used to selectively control cell behavior—a potentially valuable resource when the inclusion of proteins and growth factors is not clinically possible and a requisite tool to move beyond single-tissue repair to complex multitissue regeneration. Biomaterials-based tissue engineering has also historically included the use and delivery of signaling molecules, such as growth factors, generally

one or two at a time, but advances in materials science have permitted multiplexed delivery with greater quantitative and temporal control over delivery kinetics and more sophisticated biochemical modifications, owing in part to the availability of new polymer subtypes.

Advanced biomaterials will play an important role in translating regenerative engineering to humans. Whereas other technologies aimed at regeneration encounter difficulties in translating functional characteristics from mouse to rabbit to larger animals to humans (effector molecules like BMP-2, for instance, which requires supraphysiological concentrations to obtain a physiological response), biomaterials have been found in many settings to have better functional outcomes in larger versus smaller animals and, in some cases, may have similar inductive capacity to effector molecules, capable of differentiating undifferentiated stem cells toward prescribed lineages.

STEM CELL SCIENCE

Recently, the Society for Biomaterials challenged each of six National Academy members to describe their perceived grand challenge for the field over the next 25 years (3). Limb regeneration was put forth by Laurencin to be one of the primary challenges. Although signaling molecules will continue to be an important regenerative engineering tool toward this challenge, cells represent the fundamental building block of new tissues. Recent and continuing advances in stem cell technology will play an essential role moving forward, especially in areas such as whole-limb regeneration. Whereas tissue engineering has largely focused on primary cells isolated from targeted tissues, regenerative engineering has set its sights on stem cell technology. What has become clear over the past decade is that cells alone are not enough—they need scaffolds or materials for physical structure to retain cell populations after implantation, to guide multipotential cells that are recruited or delivered to the repair site, or to provide a template for cells to lay down new extracellular matrices. The capacity for a synthetic substrate to be the driver of these cells toward multiple lineages solely through material-based cues is emerging, with many of these cues at the nanoscale as substrate-surface modifications. These inducible materials are now being designed with specific cell lineages in mind so as to allow distinct tissue types to regenerate next to one another. Micro- and nanoscale fabrication techniques will further this goal.

THE ROLE OF DEVELOPMENTAL BIOLOGY

Challenges associated with attaching macromolecules to scaffolds for subsequent delivery have encouraged small-molecule delivery. Many small molecules have shown great efficacy in promoting tissue regeneration, in some cases recapitulating cues from developmental biology; for example, cyclic adenosine 5'-monophosphate (cAMP), which is found ubiquitously in mammalian cells and acts as a messenger to other molecules to control diverse cellular processes such as differentiation and morphogenesis. Our group has recently demonstrated that a cAMP-dependent protein kinase (PKA)-specific cAMP derivative promotes *in vitro* osteoblastic differentiation in osteoblast-like cells and mesenchymal stem cells (5), suggesting that cAMP/PKA signaling is important for osteogenesis. Beyond bone, dibutyryl cAMP enhances cartilage differentiation in the limb-bud mesoderm both in cell cultures and in organ cultures (6), suggesting that there is a role for this small molecule in complex tissue regeneration. The goal moving forward is to identify similar molecules from developmental biology that, alone or in concert with others, effect complex tissue regeneration. Such combinations could even be controlled in time so that varying morphogen or small-molecule concentrations can work synergistically to guide tissue development or regeneration. Advanced biomaterials can be designed to impart spatiotemporal control over molecule release kinetics or to prevent effector molecule release and adhere them to the material, depending on the needs of the tissue being regenerated.

THE NEXT 25 YEARS

We wish to mention some important caveats. First, regenerative engineering will not be a panacea. Novel treatments and cures will not come easily and quickly, but they will come. The toolbox that we have discussed will undergo enlargement over the next 25 years to include new strategies, perhaps mergers with seemingly disparate technologies, such as biophysics, smart bionics, and the healing power of the mind. As surgeons, we have always admired the ability of the body to self-heal. Finding ways to control and augment these self-healing mechanisms will be an important goal in regenerative engineering.

As we look forward to the next 25 years, we feel that moving beyond individual tissue repair to complex tissues (3) and biological systems is necessary. This concerted regenerative engineering effort capitalizes on the concept of convergence (4) by incorporating advanced materials science, stem cell science, and developmental biology. With the regenerative toolbox described above, we feel that regenerative engineering will allow for exciting and dynamic choices for tackling important clinical challenges.

– Cato T. Laurencin and Yusuf Khan

1. R. Langer, J. P. Vacanti, Tissue engineering. *Science* **260**, 920–926 (1993).
2. C. T. Laurencin, A. A. Ambrosio, M. D. Borden, J. A. Cooper, in *Annual Review of Biomedical Engineering*, M. L. Yarmush, Ed. (Annual Reviews, Palo Alto, 1999), pp. 19–46.
3. W. M. Reichert, B. D. Ratner, J. Anderson, A. Coury, A. S. Hoffman, C. T. Laurencin, D. Tirrell, 2010 Panel on the biomaterials grand challenges. *J. Biomed. Mater. Res. A* **96A**, 275–287 (2011).
4. P. A. Sharp, R. Langer, Research agenda. Promoting convergence in biomedical science. *Science* **333**, 527 (2011).
5. K. W. Lo, H. M. Kan, K. M. Ashe, C. T. Laurencin, The small molecule PKA-specific cyclic AMP analogue as an inducer of osteoblast-like cells differentiation and mineralization. *J. Tissue Eng. Regen. Med.* **6**, 40–48 (2012).
6. R. A. Koster, M. P. Savage, Studies on the possible role of cyclic AMP in limb morphogenesis and differentiation. *J. Embryol. Exp. Morphol.* **56**, 91–105 (1980).

